VVV. A. Vaskovskiy

V. A. Vaskovskiy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. A. Vaskovskiy has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Possibilities of stereotactic body radiotherapy for the treatment of ventricular arrhythmias: current state of the art

    by A. V. Mazurok, V. A. Vaskovskiy, N. A. Antipina, A. Sh. Revishvili, А. В. Мазурок, В. А. Васковский, Н. А. Антипина, А. Ш. Ревишвили

    This review article examines current approaches to the use of Stereotactic Arrhythmia Radioablation (STAR) in patients with sustained ventricular tachycardia refractory to medical therapy and catheter ablation. The biophysical and molecular mechanisms of the therapeutic action of the method, experimental data, principles of target planning and imaging, as well as international and our own clinical experience with the method in patients with ventricular tachycardias are presented. Technical aspects of the method, unresolved issues, limitations, and the potential for implementing STAR into Russian clinical practice are discussed separately.

  • Open Access

    Stereotactic radioablation of refractory ventricular tachycardia originating from the left ventricular summit: a case report

    by V. A. Vaskovsky, A. V. Mazurok, N. A. Antipina, A. Sh. Revishvili, В. А. Васковский, А. В. Мазурок, Н. А. Антипина, А. Ш. Ревишвили

    Цель: рефрактерная желудочковая тахикардия из труднодоступных субэпикардиальных зон, в частности саммита левого желудочка, остаётся нерешённой клинической проблемой при исчерпании возможностей катетерной аблации и медикаментозной терапии. Стереотаксическая радиоаблация (STAR) представляет перспективную неинвазивную альтернативу в данной клинической ситуации. Цель работы представить клинический случай применения STAR у молодой пациентки с рефрактерной желудочковой тахикардией из антеробазальной части (саммита) левого желудочка на фоне постмиокардитического субстрата. Материал и методы: аритмогенный субстрат верифицирован методом инвазивного электроанатомического картирования с последующей интеграцией электрофизиологических данных с результатами МРТ сердца и топографической привязкой к 17-сегментарной схеме строения левого желудочка (AHA). На основании совмещённых данных сформированы клинический объём мишени CardTV (10,43 смі) и планируемый объём облучения PTV (22,74 смі). На роботизированной системе CyberKnife M6 с адаптивным слежением за дыхательным циклом (система Synchrony) и временным электродом коронарного синуса в качестве внутрисердечного рентгенконтрастного маркера выполнено однофракционное облучение в дозе 25,5 Гр на 95% CardTV. Результаты: при выписке (8-е сутки) эктопическая нагрузка снизилась с 28 690 до 3 426 ЖЭС/сут. при полном исчезновении ЖТ. Через 4,5 месяца нагрузка составила 3 041 ЖЭС/сут., ЖТ не регистрировалась. По данным МРТ выявлены признаки формирующегося пострадиационного фиброза и реактивного миоперикардита. Заключение: STAR обеспечила выраженный и устойчивый антиаритмический эффект у пациентки с рефрактерной ЖТ при отсутствии рецидива за 4,5 месяца наблюдения. Метод может рассматриваться как альтернатива при исчерпании возможностей катетерной аблации.

  • Open Access

    Intraoperative monitoring of intraesophageal temperature during radiofrequency ablation of the posterior wall of the left atrium in atrial fibrillation (literature review)

    by M. V. Yashkov, E. A. Artyukhina, I. A. Taymasova, E. V. Dedukh, V. A. Vaskovskiy, N. M. Kuznetsov, A. Sh. Revishvili, A. Yu. Popov

    Currently catheter radiofrequency ablation (RFA) has become the standard treatment for patients with atrial fibrillation (AF). During RFA, additional linear lesions are performed along the posterior wall of the left atrium, which can cause damage to the esophagus. The manuscript considers the methods introduced into practice to prevent damage to the esophagus during RFA, the pros and cons of the techniques.

  • Open Access

    Intraoperative monitoring of intraesophageal temperature during radiofrequency ablation of the posterior wall of the left atrium in atrial fibrillation (literature review)

    by M. V. Yashkov, E. A. Artyukhina, I. A. Taymasova, E. V. Dedukh, V. A. Vaskovskiy, N. M. Kuznetsov, A. Sh. Revishvili, A. Yu. Popov

    Currently catheter radiofrequency ablation (RFA) has become the standard treatment for patients with atrial fibrillation (AF). During RFA, additional linear lesions are performed along the posterior wall of the left atrium, which can cause damage to the esophagus.The manuscript considers the methods introduced into practice to prevent damage to the esophagus during RFA, the pros and cons of the techniques.

  • Open Access

    Stereotactic radioablation in clinical practice for the treatment of a patient with ventricular tachycardia: case report

    by A. Sh. Revishvili, В. А. Васковский, E. A. Artyukhina, I. A. Taymasova, A. V. Golanov, N. A. Antipina, A. A. Nikolayeva, E. V. Kondratyev, D. Yu. Usachev

    The aim of the study is the demonstration of the 1st clinical experience of stereotactic arrhythmia radioablation (STAR) of the patient with antiarrhythmic drug (AAD) refractory ventricular tachycardia (VT) in Russia. The results of STAR of 57 years old patient with AAD and multiple radiofrequency ablation refractory VT are described. This clinical study demonstrates efficacy and safety of STAR of VT.


  • Open Access

    Long-term results of cardiac contractility modulation in patients with chronic heart failure

    by A. Yu. Amiraslanov, V. A. Vaskovskiy, E. A. Artyukhina, A. Sh. Revishvili

    Aim. Evaluate the overall effectiveness of cardiac contractility modulation (CCM) therapy in patients with chronic heart failure of various etiology.Methods. The study included 61 patients with chronic heart failure (NYHA class II-III), ejection fraction 20-40% and narrow QRS 1 in 29 (53.7%) patients (р=0.015), increased 6-min walk test from 265 to 343 m (р=0.029), and the MHFLQ improved from 46.1 to 35.8 (р=0.042). Non-ischemic cardiomyopathy was associated with significant improvement in MHFLQ (from 42.7 to 30.3, р=0.029) and lowering the heart failure NYHA class>1 (83.3%, vs 47.2%, p=0.012) compared to ischemic group. Conclusion. CCM is safe and effective in patients with chronic heart failure NYHA class II-III, ejection fraction 20- 40% and narrow QRS˂130 ms, who were implanted the CCM devices. Depending on the etiology of heart failure, ischemic cardiomyopathy prevailed (41 patients). All patients were performed echocardiography, 6-min walk test and Minnesota Living with Heart Failure questionnaire (MHFLQ).Results. The observation period was 25 months. All 54 patients significantly improved left ventricular ejection fraction from 32.2% to 37.6% (р=0.026) and volume parameters (left ventricle end systolic volume from 150 to 137 ml (р=0.034), left ventricle end diastolic volume from 220 to 201 ml (р=0.044), reduced the heart failure NYHA class >1 in 29 (53.7%) patients (р=0.015), increased 6-min walk test from 265 to 343 m (р=0.029), and the MHFLQ improved from 46.1 to 35.8 (р=0.042). Non-ischemic cardiomyopathy was associated with significant improvement in MHFLQ (from 42.7 to 30.3, р=0.029) and lowering the heart failure NYHA class>1 (83.3%, vs 47.2%, p=0.012) compared to ischemic group.Conclusion. CCM is safe and effective in patients with chronic heart failure NYHA class II-III, ejection fraction 20- 40% and narrow QRS˂130 ms. Non-ischemic etiology of cardiomyopathy was associated with significant improvement in MHFLQ and lowering the heart failure class.


  • Assessment of Biocompatibility and Local Action of Biomaterial for Production of an Envelope for Implanted Heart Electronic Devices

    by D. V. Shadrina, A. A. Venediktov, S. V. Evdokimov, V. A. Vaskovskii, E. A. Artyukhina, A. Sh. Revishvili, S. S. Durmanov, V. V. Bazylev

    We studied a biomaterial for a new domestic product, a biological envelope for implantation of cardiac electronic devices. The product is designed to prevent complications after pacemaker implantation and to facilitate the reimplantation procedure. By chemical and biological processing of raw materials (submucosa of porcine small intestine), an acellular extracellular collagen matrix was obtained. The biocompatibility of the material was tested in vitro using stem cell cultures. The biomaterial for fabrication of the envelope is not cytotoxic, biocompatible, and represents a suitable substrate for attachment, growth, and reproduction of stem cells. The biological effect of the material was studied in vivo on the model of heterotopic implantation in small laboratory animals. The biomaterial did not induce inflammation and tissue reaction and was completely transformed into healthy vascularized tissue without scars in 90 days after implantation.


  • Open Access

    EVALUATION OF THE FUNCTIONAL PROPERTIES OF A BIOLOGICAL CASE FOR IMPLANTABLE CARDIAC DEVICES, IMPREGNATED WITH BIOACTIVE SUBSTANCES IN AN EXPERIMENT ON LARGE LABORATORY ANIMALS

    by E. A. Artukhina, V. A. Vaskovskiy, A. A. Venediktov, S. V. Evdokimov, S. S. Durmanov, I. A. Evtjushkin, V. V. Bazylev, A. Sh. Revishvil

    Aim. The purpose of the experimental study was to determine the functional properties of the case with antibacterial and hemostatic preparations impregnated on it, to assess the biological safety and the effectiveness of using this medical device in an in vivo model on large laboratory animals (pigs).Material and Methods. The article presents the first results of an experimental study of a domestic extracellular collagen matrix-based biological case “Bio-NEST” for implantable cardiac devices, impregnated with bioactive substances, in an in vivo experiment on large laboratory animals. The experiment was conducted in three chronological stages to analyze and evaluate the safety, efficacy, and histological compatibility of the biological sheath during implantation and reimplantation of cardiac devices using bioactive substances (antibacterial, hemostatic, and their combinations) as well as under the conditions of the established model of infection with pathogenic microflora implant pocket.Results. Results of the study showed that the use of the experimental cover sample was safe for a laboratory animal. Experimental samples were biocompatible and did not cause inflammatory and immune responses. Implantation of cardiac devices in the sample of the case allowed preventing implant migration and development of infectious inflammation of the implant bed when the experimental cover was impregnated with a solution of rifampicin and aminocaproic acid.


  • Open Access

    OPPORTUNITIES AND FUTURE PERSPECTIVES FOR REMOTE MONITORING OF PATIENTS WITH IMPLANTED DEVICES

    by N. N. Lomidze, V. A. Vaskovskiy, M. V. Yashkov, E. A. Artukhina, A. Sh. Revishvili

    Today implantable cardiac devices (ICD) are advanced therapeutic and preventive tools ensuring the collection and transmission of statistical and diagnostic patient data. The information obtained from implanted devices allows analyzing patients’ condition, selecting optimal treatment strategy, predicting and preventing possible complications. The number of ICD recipients is rapidly growing. Over 1,000 devices per 1 million population are implanted in Europe and the US annually. In the Russian Federation this number reaches 300 devices per 1 million population. Routine medical checkups of patients with ICD should be performed 2–4 times a year, with an average length of about 20 minutes. It means that only in the Russian Federation physicians will have to work 20–40 thousand extra hours with a tendency towards its increase as this figure will grow simultaneously with growing patients’ number. Remote monitoring (RM) technologies may solve this problem. In 2000 Biotronik AG developed the world's first system for remote monitoring of anti-arrhythmic devices called the “Home Monitoring” system. It is based on the mobile RM of patients who received ICD. The information collected by the devices is transmitted to a special service center via mobile communication networks and after processing, the information is transferred to a physician’s website along with a text message and a fax. The information is instantly delivered from a patient to a physician. A closed information network "patient-service center-physician" was developed for the hospitals and their patients, providing a novel advanced monitoring and timely treatment of the patient.


  • Isolated Atrial Amyloidosis in Patients with Various Types of Atrial Fibrillation

    by T. V. Sukhacheva, M. V. Eremeeva, A. G. Ibragimova, V. A. Vaskovskii, R. A. Serov, A. Sh. Revishvili

    The myocardium of the right and left atrial appendages (auricles) in patients with paroxysmal, persistent, and permanent forms of atrial fibrillation was examined by histological methods and electron microscopy. Isolated atrial amyloidosis was detected in the left (50.0-56.3% patients) and in the right (45.0-55.6% patients) atrial appendages. In all cases, immunohistochemistry revealed atrial natriuretic peptide in fibrillary amyloid deposits. Ultrastructurally, amyloid masses formed clusters of myofibrils 8-10 nm in diameter. They were chaotically located in the extracellular space along the sarcolemma as well as in membrane invaginations, dilated tubules of cardiomyocyte T-tubular system, and vascular walls. Amyloidosis was predominantly observed in women; its degree positively correlated with age of patients and duration of atrial fibrillation but negatively correlated with atrial fibrosis. The study revealed positive (in permanent atrial fibrillation) and negative (in paroxysmal atrial fibrillation) correlation of amyloidosis with myofibril content in atrial cardiomyocytes.